Sentences with phrase «clinical trial study with»

We performed a randomized clinical trial study with long - term follow up.

They performed a randomized clinical trial study with long - term follow up.

Not exact matches

The Chinese government financed nationwide studies into cockroaches» medical value that, after more than two decades of laboratory investigation and clinical trials, had discovered or confirmed dozens of disease - fighting proteins and biochemical compounds with huge potential value in medicine.

Currently in the U.K., he will go back to Privateer's headquarters in Seattle, then visit Tilray's 60,000 - square foot facilities in British Columbia, Canada, then to Australia, where Tilray has an import license to send marijuana for a clinical trial with a chemotherapy - induced nausea and vomiting study with the University of Sydney, the government of New South Wales and the country's largest cancer hospital.

Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.

Swiss drug giant Novartis is partnering with California - based Science 37 in an effort to expand clinical study participation (while lowering the costs of such studies) through «virtual» trials.

Studies — including at least one clinical trial with 100 participants — have found that this diet can significantly alter signs of disease, reduce weight and body fat, lower blood pressure, decrease levels of biomarkers associated with cancer, and improve blood - sugar levels.

NOVARTIS PARTNERS WITH SCIENCE 37 TO DEVELOP «VIRTUAL TRIALS»: Swiss drugmaker Novartis announced plans to work with virtual clinical trial company Science 37 to develop «remote trial» technology that uses video conferencing to lower the barrier of entry for recruiting study participants, according to ReutWITH SCIENCE 37 TO DEVELOP «VIRTUAL TRIALS»: Swiss drugmaker Novartis announced plans to work with virtual clinical trial company Science 37 to develop «remote trial» technology that uses video conferencing to lower the barrier of entry for recruiting study participants, according to Reutwith virtual clinical trial company Science 37 to develop «remote trial» technology that uses video conferencing to lower the barrier of entry for recruiting study participants, according to Reuters.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The company's leading program, a differentiated PPAR gamma agonist (MIN - 102) that has multiple CNS indications, has successfully completed a phase 1 clinical trial and is ready to move into a phase 2/3 study with adult AMN patients.

All study participants gave written informed consent and the study was approved by the Monash University Human Research Ethics Committee (approval number CF12 / 0348 -2012000146), and the trial registered with the Australia and New Zealand Clinical Trial Registry (registration number 12611000468trial registered with the Australia and New Zealand Clinical Trial Registry (registration number 12611000468Trial Registry (registration number 12611000468921).

The PhD course focuses on various aspects of human (donor) milk, with as main study a randomized clinical trial towards the effects of human donor milk in very low birth weight infants (the Early Nutrition Ststudy a randomized clinical trial towards the effects of human donor milk in very low birth weight infants (the Early Nutrition StudyStudy).

This study is a randomized clinical trial (RCT) with 50 mother / infant pairs in the intervention arm, 50 in one control group and 25 in a third control group.

We conducted our study in conjunction with the clinical trials and epidemiology research unit, which is an independent organisation funded by the National Medical Research Council.

The bill would make it mandatory for researchers to publish all information from cancer clinical trials, with the goal being to get more researchers to work together and bring down the number of duplicative studies.

Since in science no one study is a final answer, CTT gathers data from numerous clinical trials and feeds them into a meta - analysis — a calculation that combines data from different studies to come up with a wide - angle view.

Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancer.

A one - time intravenous infusion of the high dose of gene therapy extended the survival of patients with spinal muscular atrophy type 1 (SMA1) in a Phase 1 clinical trial, according to a study published in the New England Journal of Medicine.

«The study results elucidate the molecular mechanisms underlying disease progression in multiple sclerosis models, providing a basis for future clinical trials to determine safety and efficacy of these chemical agents in humans with demyelinating disorders,» says Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomic Sciences at Mount Sinai and senior author of the study.

«Complex models are needed to effectively evaluate PMed study designs, and this proof - of - concept trial validates the dog with cancer as a model for clinical evaluation of novel PMed approaches,» said Dr. Melissa Paoloni, the study's lead author and former director of the COTC.

In this new study and for the first time, scientists used functional magnetic resonance imaging (fMRI) combined with a standard clinical trial design to derive an unbiased brain - based neurological marker to predict analgesia associated with placebo treatment in patients with chronic knee osteoarthritis pain.

Participants in the study included 588 men diagnosed with intermediate risk prostate cancer (i.e., clinical stage T1c - T2b) and enrolled in the trial between 2003 and 2012.

«We believe these studies and clinical trials that combine immunotherapy with chemotherapy are advancing efforts toward better clinical care and more positive outcomes for our patients at CTCA,» said Dr. Vivek Khemka, Medical Oncologist, CTCA at Western and the WCLC study abstract's principal investigator and senior author.

The first clinical trial of a drug intended to delay the onset of symptoms of Huntington disease (HD) reveals that high - dose treatment with the nutritional supplement creatine was safe and well tolerated by most study participants.

The Phase I clinical trial of OMP - 54F28 (FZD8 - Fc) is an open - label dose escalation study in patients with advanced solid tumors for which there was no remaining standard curative therapy.

Nonetheless, this July, the FDA suspended enrollment in Glaxo's large clinical trial comparing the safety of Avandia with that of a competing diabetes drug and may halt the study altogether.

These techniques include: human tissue created by reprogramming cells from people with the relevant disease (dubbed «patient in a dish»); «body on a chip» devices, where human tissue samples on a silicon chip are linked by a circulating blood substitute; many computer modelling approaches, such as virtual organs, virtual patients and virtual clinical trials; and microdosing studies, where tiny doses of drugs given to volunteers allow scientists to study their metabolism in humans, safely and with unsurpassed accuracy.

In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.

People diagnosed with cancer gained 3.34 million years of life thanks to cancer clinical trials run by SWOG and supported with public funds, according to new study results to be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the world's largest clinical cancer research clinical trials run by SWOG and supported with public funds, according to new study results to be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the world's largest clinical cancer research Clinical Oncology (ASCO), the world's largest clinical cancer research clinical cancer research meeting.

«Our study shows the significant impact of adding carotid plaque measurement using vascular ultrasound and coronary calcium scoring with CT scan to our conventional assessment for cardiovascular disease,» says Roxana Mehran, MD, the study's co-lead author and Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai Heart at Icahn School of Medicine at Mount Sinai.

Another problem is that modeling studies, like this one, are inherently less powerful than other kinds of medical research: randomized clinical trials, the gold standard in medical research, in which patients are randomly assigned different treatments or no treatment; case - control studies, which compare patients who have a condition with those who do not; or cohort studies, which determine the risk of contracting a disease by studying a group of people with similar demographics.

The authors do note that this large study can not definitively prove cause and effect; nonetheless, the findings are strongly consistent with «a wealth of existing observational and clinical trial data to support health benefits of nut consumption on many chronic diseases.»

Last month, Biopure launched a revamped clinical development program, emphasizing testing in Europe, with three phase II clinical trials planned for 2008 to study the impact of its product on heart attack patients, chemotherapy patients with anemia and the terminally ill.

The epidemiological evidence was strong enough that it led to a whole series of clinical studies and randomized control trials with fish oil, says nutritionist Penny M. Kris - Etherton of Pennsylvania State University.

The next step, says Salem, will be to try to correlate these findings with patient treatment outcomes, initially as a retrospective, or backward looking study, and then hopefully design a forward looking clinical trial to determine which treatments may be best for patients with SBAs.

«The current landscape of stem cell tourism should prompt a re-evaluation of current approaches to study cell - based interventions with respect to the design, initiation and conduct of U.S. clinical trials,» the authors wrote.

Once we have demonstrated the proof of concept in animal studies, the next goal will be to work towards the first human clinical trial with graphene devices during intraoperative mapping of the brain.

«It was clear from our findings that many people with IBS should have their vitamin D levels tested, and the data suggests that they may benefit from supplementation with vitamin D. «As a result of this exploratory study, we're now able to design and justify a larger and more definitive clinical trial.»

The new study is a meta - analysis of three randomized controlled trials conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B)(CALGB) with support from the NCI, Intergroupe Francophone du Myélome (IFM), and the Gruppo Italiano Malattie Ematologiche dell «Adulto (GItrials conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B)(CALGB) with support from the NCI, Intergroupe Francophone du Myélome (IFM), and the Gruppo Italiano Malattie Ematologiche dell «Adulto (GITrials in Oncology (formerly Cancer and Leukemia Group B)(CALGB) with support from the NCI, Intergroupe Francophone du Myélome (IFM), and the Gruppo Italiano Malattie Ematologiche dell «Adulto (GIMEMA).

Dr. Criner said that despite the clinical trial's finding that the statin drug did not help with COPD flare - ups, information gleaned from this study should help inform other research into the inflammatory nature of COPD.

In my experience, this marks both the first clinical trial of an approved drug with an effect on survival in advanced melanoma in the adjuvant setting, and, in this same setting, the first to study an immune checkpoint inhibitor in the adjuvant setting.

«Not only do we believe that high - quality, randomized clinical trials are necessary to determine the safety of the Lariat device for off - label procedures, but our analysis raises broader issues with the FDA 510 (k) clearance protocol for medical devices,» said study senior author Jay Giri, MD, MPH, assistant professor in the Cardiovascular Medicine Division at Penn. «We believe there needs to be a method for reassessing the safety of a device that has been cleared for one use but is being frequently used for a different purpose in real - world practice.»

The clear result of this clinical study — that the combination reduced strokes, heart attacks and cardiovascular death by practically 25 per cent compared to either drug alone in both patients with stable coronary or peripheral artery disease — caused the clinical trial to be stopped early, after 23 months, in February 2017.

He was part of a Northwestern Medicine and Hines V.A. clinical trial that studied whether repeated stimulation with familiar voices could help repair a coma victim's injured brain networks and spur his recovery.

Independent of these preclinical studies, Clementia Pharmaceuticals is currently conducting phase 2 clinical trials in individuals with FOP, based on the 2011 preclinical results published by Pacifici and Iwamoto.

Diamond is also quick to point out that while the current study shows that COXEN could have been used to predict the most useful drug in many of these cases of advanced ovarian cancer, the actual use of the model will be possible only after validation with a prospective clinical trial.

During a conversation this month in his office at Weill Cornell Medicine in New York City, Fine rattled off more dismal stats, like the many failed clinical trials of experimental drugs for glioblastoma; like the paltry increase in life expectancy for people with glioblastoma from 12 months in 1990 to 15 today; like the stupid (in hindsight) assumptions about how glioblastomas grow and how to study them in mice.

A clinical trial studying the use of Verapamil (a drug currently in use for cardiovascular disease and cluster headache) in alleviating chronic rhinosinusitis (CRS) with nasal polyps revealed significant improvement in the symptoms of this subset of patients.

The study included 124 newly diagnosed patients at 25 clinical trial sites in the U.S. Two - thirds of the patients were treated with ICT - 107, an experimental vaccine based on immune system cells called dendritic cells that were exposed to six synthetic proteins, or antigens, known to be involved in GBM development.

Aggressive treatment of high blood pressure comes with risks, and the study, a large clinical trial sponsored by the National Institutes of Health, has not yet been peer - reviewed or published.